UniSa - IRIS Institutional Research Information System

ERRO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 17.841
NA - Nord America 10.850
EU - Europa 4.769
SA - Sud America 2.030
Continente sconosciuto - Info sul continente non disponibili 620
AF - Africa 210
OC - Oceania 67
Totale 36.387
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 11.523
US - Stati Uniti d'America 10.486
SG - Singapore 2.751
IT - Italia 2.180
BR - Brasile 1.549
CN - Cina 1.155
VN - Vietnam 1.117
RU - Federazione Russa 532
UA - Ucraina 372
IE - Irlanda 319
DE - Germania 313
TR - Turchia 309
FR - Francia 289
KR - Corea 239
SE - Svezia 195
AR - Argentina 183
CA - Canada 174
GB - Regno Unito 160
BD - Bangladesh 153
IN - India 136
MX - Messico 91
ID - Indonesia 88
JP - Giappone 81
EC - Ecuador 79
FI - Finlandia 77
CO - Colombia 71
IQ - Iraq 61
NL - Olanda 58
ZA - Sudafrica 58
PL - Polonia 54
ES - Italia 39
EE - Estonia 37
VE - Venezuela 37
AU - Australia 36
AT - Austria 32
MA - Marocco 32
PK - Pakistan 30
PY - Paraguay 30
CL - Cile 28
NZ - Nuova Zelanda 28
KE - Kenya 25
UZ - Uzbekistan 25
UY - Uruguay 21
EG - Egitto 19
CR - Costa Rica 18
CZ - Repubblica Ceca 18
PE - Perù 18
DZ - Algeria 17
JO - Giordania 17
SA - Arabia Saudita 16
JM - Giamaica 15
PH - Filippine 14
TN - Tunisia 14
AL - Albania 12
BO - Bolivia 12
LB - Libano 12
MY - Malesia 12
NP - Nepal 12
AE - Emirati Arabi Uniti 11
DO - Repubblica Dominicana 11
LT - Lituania 11
AZ - Azerbaigian 10
KZ - Kazakistan 10
IL - Israele 9
CH - Svizzera 8
PA - Panama 8
ET - Etiopia 7
GR - Grecia 7
IR - Iran 7
NI - Nicaragua 7
PR - Porto Rico 7
BE - Belgio 6
CI - Costa d'Avorio 6
HN - Honduras 6
KW - Kuwait 6
SV - El Salvador 6
TH - Thailandia 6
BG - Bulgaria 5
HU - Ungheria 5
MD - Moldavia 5
NO - Norvegia 5
OM - Oman 5
RS - Serbia 5
SN - Senegal 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
BY - Bielorussia 3
CY - Cipro 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
KG - Kirghizistan 3
MU - Mauritius 3
SI - Slovenia 3
SO - Somalia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
Totale 35.713
Salva come PNG Salva come JPEG
Città #
Hong Kong 11.509
Singapore 1.330
San Jose 1.230
Ann Arbor 1.219
Milan 899
Princeton 849
Dallas 709
Ashburn 663
Chandler 539
Wilmington 497
Jacksonville 432
Ho Chi Minh City 357
Council Bluffs 325
Dublin 309
Beijing 300
The Dalles 276
Izmir 265
Lauterbourg 255
Woodbridge 216
Rome 215
Houston 211
Hanoi 206
Salerno 187
Los Angeles 183
Dong Ket 162
New York 159
Moscow 155
Santa Clara 153
São Paulo 129
Andover 127
Pellezzano 121
Naples 119
Nanjing 115
Figino 88
Norwalk 73
Tokyo 73
Boardman 69
Fairfield 62
Frankfurt am Main 57
Buffalo 55
Munich 53
Rio de Janeiro 50
Orem 49
Nuremberg 48
Chicago 47
Da Nang 47
Haiphong 46
Turin 45
Düsseldorf 44
Shenyang 44
Montreal 43
Warsaw 43
Brasília 41
Pune 38
Tallinn 37
Hebei 36
Curitiba 35
Nanchang 34
San Francisco 34
Boston 33
Brooklyn 33
Changsha 33
Denver 32
Atlanta 31
Belo Horizonte 29
Columbus 29
Dearborn 29
London 29
Seoul 29
Johannesburg 28
Seattle 28
Toronto 28
Mestre 27
Mexico City 27
San Diego 27
West Jordan 27
Amsterdam 26
Jiaxing 26
Baghdad 25
Guayaquil 25
Stockholm 25
Phoenix 24
Quito 24
Tashkent 24
Nairobi 23
Porto Alegre 23
Washington 23
Fortaleza 22
Redwood City 22
Guarulhos 21
Bologna 20
Turku 20
Salvador 19
Uberlândia 19
Thái Bình 18
Guangzhou 17
Amman 16
Hải Dương 16
Sydney 16
Cambridge 15
Totale 26.720
Salva come PNG Salva come JPEG
Nome #
Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables 1.197
Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients 967
Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19 938
Sex Differences in Parkinson’s Disease: From Bench to Bedside 652
Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease 550
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. 549
Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study 534
Gait Analysis in Progressive Supranuclear Palsy Phenotypes. 532
Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study 518
Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy 470
Quality of Life and Nonmotor Symptoms in Parkinson's Disease 465
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 460
Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry 452
Fist-Palm Test May Identify Mild Cognitive Impairment and Freezing of Gait in Parkinson's Disease: A Machine Learning Approach 407
Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status 396
Energy expenditure, body composition and dietary habits in progressive supranuclear palsy 379
Remission in dystonia – Systematic review of the literature and meta-analysis 373
Non-invasive brain stimulation for dystonia: therapeutic implications 365
Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates 361
Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review 342
[¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. 338
Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy 316
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. 279
Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features 251
Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease 248
A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort 245
Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects 226
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 217
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 215
Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy 200
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 193
ADCY5 mutations are another cause of benign hereditary chorea 190
A window into the mind-brain-body interplay: Development of diagnostic, prognostic biomarkers, and rehabilitation strategies in functional motor disorders 187
Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers 186
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 172
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 170
Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease 167
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 159
Are granular osmiophilic material deposits an epiphenomenon in CADASIL? 158
Essential tremor plus rest tremor: current concepts and controversies 157
Cognitive behavioural therapy and adjunctive physical activity for functional movement disorders (Conversion Disorder): A pilot, single-blinded, randomized study 157
Quitting smoking: An early non-motor feature of Parkinson's disease? 156
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 155
Abnormal eating behaviors in progressive supranuclear palsy. 152
Increased bilirubin levels in de novo Parkinson's disease 152
Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy 152
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 149
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 149
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 148
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 144
Machine learning can predict mild cognitive impairment in Parkinson's disease 143
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? 142
Caffeine consumption and the 4-year progression of de novo Parkinson's disease 142
The Motor Syndrome of Parkinson's Disease 142
Spread of dystonia in patients with idiopathic adult-onset laryngeal dystonia 140
Regional gray matter atrophy in patients with Parkinson disease and freezing of gait 139
Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study 138
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 138
Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy 137
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 134
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: A 4-year longitudinal study 133
Affective and cognitive theory of mind in patients with cervical dystonia with and without tremor 133
Cerebellar and brainstem functional abnormalities in patients with primary orthostatic tremor 131
Gender and non motor fluctuations in Parkinson's disease: A prospective study 128
Early MRI findings in acquired hepatocerebral degeneration. 126
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 126
Malabsorption is uncommon in restless legs syndrome. 125
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 124
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 124
Impact of COVID-19 on neurological patients attending a botulinum toxin service 123
MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes 122
Bipolar Disorder and Parkinson’s Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study 122
Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism 121
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 121
Orthostatic myoclonus associated with Caspr2 antibodies 119
Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy 119
Comparing PIGD and Akinetic-Rigid subtyping of Parkinson Disease and their stability over time 119
The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy 117
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 117
Effects of gender on cognitive and behavioral manifestations in multiple system atrophy 116
Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. 115
Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy 115
Uric acid relates to dopamine transporter availability in Parkinson's disease. 114
On the relationship between side of onset and cognition in Parkinson disease 114
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 113
Non-motor correlates of smoking habits in de novo Parkinson's disease 113
A novel therapeutic approach for synucleinopathies 113
Presence and progression of non-motor symptoms in relation to uric acid inde novoParkinson's disease 112
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 112
A Screening Tool to Quickly Identify Movement Disorders in Patients with Inborn Errors of Metabolism 111
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 111
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 109
Midbrain MRI assessments in progressive supranuclear palsy subtypes 106
The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease 104
Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for? 104
Brittle response to levodopa as a marker of Parkinson’s disease phenotype characterized by heavy motor and non-motor burden 103
The "eye of the tiger" sign in pure akinesia with gait freezing. 103
Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials 103
“Atypical” atypical parkinsonism: Critical appraisal of a cohort 102
Levodopa-carbidopa intestinal gel is an option in Parkinson’s disease with hyponatremia induced by dopamine agonists 102
Totale 22.735
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.270 0 1 5 9 24 8 17 37 146 164 216 643
2022/20231.556 242 102 73 141 171 371 18 129 202 8 66 33
2023/20241.005 45 132 57 61 46 120 37 77 49 66 55 260
2024/20252.997 84 40 50 121 116 342 372 261 452 422 371 366
2025/202623.529 3.066 5.569 4.716 1.548 1.286 660 2.007 513 619 1.386 377 1.782
2026/20271.128 882 246 0 0 0 0 0 0 0 0 0 0
Totale 36.387